Kymera Therapeutics unveils KT-579 IBD preclinical data at DDW
Kymera Therapeutics has presented new preclinical data for KT-579, its oral degrader of the transcription factor IRF5, at Digestive Disease Week (DDW) in Chicago, showing the candidate matched or exceeded the activity of approved and late-stage comparators in a standard model of inflammatory bowel disease.
The TNBS colitis model results showed that KT-579 produced significant reductions in disease activity scores, including protection from body-weight loss and preservation of colon architecture. Complete inhibition of key pro-inflammatory cytokines — TNFα, IL-1β and IL-6 — was recorded, alongside improved crypt structure and a reduction in inflammatory infiltrates. Transcriptomic analysis indicated broad normalisation of inflammatory, myeloid and fibrosis-associated pathways, with effects described as comparable to an anti-TNF agent. The comparators in the study included a JAK inhibitor and biologic agents targeting integrins and TNF.
Mechanism and clinical status
KT-579 targets IRF5, a transcription factor that functions as a master regulator of innate and adaptive immune responses across multiple pathways simultaneously, including Type I interferons, pro-inflammatory cytokines and autoantibody production. Kymera's thesis is that this multi-pathway modulation could deliver biologics-like disease control in a convenient oral medicine — an important distinction in IBD, where injectable biologics dominate the moderate-to-severe segment.
Juliet Williams, head of research at Kymera, said that many patients with chronic inflammatory diseases "still cycle through therapies or remain inadequately controlled, in part because existing treatments don't fully address the complexity of their disease." The company reported that KT-579's activity in the IBD model was consistent with previously published preclinical data in lupus and rheumatoid arthritis models, extending the candidate's potential utility across multiple autoimmune indications.
The Phase 1 healthy volunteer trial, which is evaluating single- and multiple-ascending doses of KT-579 against placebo, is ongoing. Key endpoints include safety, tolerability, pharmacokinetics and — critically — pharmacodynamic evidence that the compound can robustly degrade IRF5 in blood at tolerated doses. Kymera expects to report Phase 1 data in the second half of 2026.
Market context
The oral IBD market is one of the most commercially contested in immunology. The JAK inhibitor class — including tofacitinib and upadacitinib — has established proof of concept for orally administered small molecules in Crohn's disease and ulcerative colitis, but the class carries a class-wide boxed warning for cardiovascular and malignancy risk that limits its use, particularly in older patients and those with cardiovascular risk factors. Selective degradation of IRF5 is a mechanistically distinct approach and, if the safety profile seen in preclinical studies translates to the clinic, could occupy a differentiated position.
Targeted protein degradation more broadly is an active area of pharmaceutical investment. Several companies — including Arvinas, C4 Therapeutics and Nurix — are developing degraders across oncology and immunology, though IRF5 as a degradation target in IBD remains, as far as is publicly known, specific to Kymera's pipeline. The pivotal question for the investment and clinical community will be whether the Phase 1 pharmacodynamic readout later this year demonstrates the depth of IRF5 degradation in circulating immune cells that the company's preclinical models have predicted. A robust PD signal in healthy volunteers would substantially de-risk the transition to patient studies.